<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        89-116-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PEPSOLAN 40 MG Powder for solution for injection 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        130.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LEK PHARMACEUTICALS D.D." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LEK PHARMACEUTICALS D.D.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pepsolan contains the active substance pantoprazole. Pepsolan is a selective &ldquo;proton pump inhibitor&rdquo;, a medicine which reduces the amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine.</p><p>This preparation is injected into a vein and will only be given to you if your doctor thinks pantoprazole injections are more suitable for you at the moment than pantoprazole tablets. Tablets will replace your injections as soon as your doctor sees fit.</p><p>&nbsp;</p><p>Pepsolan is used for treating:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reflux oesophagitis. An inflammation of your oesophagus (the tube which connects your throat to your stomach) accompanied by the regurgitation of stomach acid.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach and duodenal ulcers.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zollinger-Ellison-Syndrome and other conditions producing too much acid in the stomach.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Pepsolan :</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to pantoprazole or to any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to medicines containing other proton pump inhibitors.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before taking Pepsolan .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems. Please tell your doctor if you ever had problems with your liver in the past. He will check your liver enzymes more frequently. In the case of a rise of liver enzymes the treatment should be stopped.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking HIV protease inhibitors such as atazanavir (for the treatment of HIV-infection) at the same time as pantoprazole, ask your doctor for specific advice.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking a proton pump inhibitor like pantoprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are on Pepsolan for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are due to have a specific blood test (Chromogranin A).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a skin reaction after treatment with a medicine similar to Pepsolan that reduces stomach acid.</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with Pepsolan . Remember to also mention any other ill-effects like pain in your joints.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately</strong>, before or after taking this medicine, if you notice any of the following symptoms, which could be a sign of another, more serious, disease:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an unintentional loss of weight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting, particularly if repeated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting blood; this may appear as dark coffee grounds in your vomit</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you notice blood in your stools; which may be black or tarry in appearance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in swallowing or pain when swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you look pale and feel weak (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe and/or persistent diarrhoea, because this medicine has been associated with a small increase in infectious diarrhoea.</p><p>&nbsp;</p><p>Your doctor may decide that you need some tests to rule out malignant disease because pantoprazole also alleviates the symptoms of cancer and could cause delay in diagnosing it. If your symptoms continue in spite of your treatment, further investigations will be considered.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Pepsolan is not recommended for use in children as it has not been proven to work in children below 18 years of age.</p><p>&nbsp;</p><p>Other medicines and Pepsolan</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>This is because Pepsolan may influence the effectiveness of other medicines, so tell your doctor if you are taking:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as ketoconazole, itraconazole and posaconazole (used to treat fungal infections) or erlotinib (used for certain types of cancer) because Pepsolan may stop these and other medicines from working properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin and phenprocoumon, which affect the thickening, or thinning of the blood. You may need further checks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat HIV-infection, such as atazanavir.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate (used to treat rheumatoid arthritis, psoriasis, and cancer) &ndash; if you are taking methotrexate your doctor may temporarily stop your Pepsolan treatment because pantoprazole can increase levels of methotrexate in the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluvoxamine (used to treat depression and other psychiatric diseases) &ndash; if you are taking fluvoxamine your doctor may reduce the dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (used to treat infections).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression).</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>There are no adequate data from the use of pantoprazole in pregnant women. Excretion into human milk has been reported.</p><p>&nbsp;</p><p>If you are pregnant or breast feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>You should use this medicine, only if your doctor considers the benefit for you greater than the potential risk for your unborn child or baby.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Pepsolan has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>If you experience side effects like dizziness or disturbed vision, you should not drive or operate machines.</p><p>&nbsp;</p><p>Pepsolan contains sodium</p><p>This medicine contains less than 1 mmol (23 mg) sodium per vial, that is to say essentially sodium</p><p>free.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your nurse or your doctor will administer the daily dose to you as an injection into a vein over a period of 2 - 15 minutes.</p><p>&nbsp;</p><p>The recommended dose is:</p><p>Adults</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>For gastric ulcers, duodenal ulcers and reflux oesophagitis.</em></p><p>One vial (40 mg pantoprazole) a day.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>For the long-term treatment of Zollinger-Ellison syndrome and other conditions in which too much stomach acid is produced.</em></strong></p><p>Two vials (80 mg pantoprazole) a day.</p><p>&nbsp;</p><p>Your doctor may later adjust the dose, depending on the amount of stomach acid you produce. If you are prescribed more than two vials (80 mg) a day, the injections will be given in two equal doses.</p><p>Your doctor may prescribe a temporary dose of more than four vials (160 mg) a day. If your stomach acid level needs to be controlled rapidly, a starting dose of 160 mg (four vials) should be enough to lower the amount of stomach acid sufficiently.</p><p>&nbsp;</p><p>Hepatic impairment</p><p>If you suffer from severe liver problems, the daily injection should be only 20 mg (half a vial).</p><p>&nbsp;</p><p>Use in children and adolescents</p><p>These injections are not recommended for use in children and adolescents under 18 years.</p><p>&nbsp;</p><p>If you use more Pepsolan than you should</p><p>These doses are carefully checked by your nurse or your doctor so an overdose is extremely unlikely. There are no known symptoms of overdose.</p><p>&nbsp;</p><p>If you have any further questions about the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you get any of the following side effects, tell your doctor immediately, or contact the casualty department at your nearest hospital:</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious allergic reactions (frequency rare: may affect up to 1 in 1,000 people)</strong>: swelling of&nbsp; the tongue and/or throat, difficulty in swallowing, hives (nettle rash), difficulties in breathing, allergic facial swelling (Quincke&rsquo;s oedema / angioedema), severe dizziness with very fast heartbeat and heavy sweating.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious skin conditions (frequency not known: frequency cannot be estimated from the available data): </strong>blistering of the skin and rapid&nbsp;&nbsp; &nbsp;deterioration of your general condition, erosion (including slight bleeding) of eyes, nose, mouth/lips or genitals (Stevens-Johnson-Syndrome, Lyell-Syndrome, Erythema multiforme) and sensitivity to light.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other serious conditions (frequency not known: frequency cannot be estimated from the available data): </strong>yellowing of the skin or whites of the eyes (severe damage to liver cells, jaundice) or fever, rash, and enlarged kidneys sometimes with painful urination and lower back pain (serious inflammation of the kidneys), possibly leading to kidney failure.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Other side effects are:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Common </strong>(may affect up to 1 in 10 people)</p><p>inflammation of the wall of the vein and blood clotting (thrombophlebitis) where the medicine is injected; benign polyps in the stomach.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>headache; dizziness; diarrhoea; feeling sick, vomiting; bloating and flatulence (wind); constipation; dry mouth; abdominal pain and discomfort; skin rash, exanthema, eruption; itching; feeling weak, exhausted or generally unwell; sleep disorders; fracture in the hip, wrist or spine.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>distortion or complete lack of the sense of taste; disturbances in vision such as blurred vision; hives; pain in the joints; muscle pains; weight changes; raised body temperature; high fever; swelling of the extremities (peripheral oedema); allergic reactions; depression;&nbsp; breast&nbsp; enlargement in males.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Very Rare </strong>(may affect up to 1 in 10,000 people) disorientation.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>hallucination, confusion (especially in patients with a history of these symptoms); decreased sodium level in blood, decreased magnesium level in blood (see section 2); feeling of tingling, prickling, pins and needles, burning sensation or numbness, rash, possibly with pain in the joints; inflammation in the large bowel, that causes persistent watery diarrhoea.</p><p>&nbsp;</p><p>Side effects identified through blood tests:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon </strong>(may affect up to 1 in 100 people) an increase in liver enzymes.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>an increase in bilirubin; increased fat levels in blood; sharp drop in circulating granular white blood cells, associated with high fever.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Very Rare </strong>(may affect up to 1 in 10,000 people)</p><p>a reduction in the number of blood platelets, which may cause you to bleed or bruise more than normal;&nbsp; a&nbsp; reduction&nbsp; in&nbsp; the&nbsp; number&nbsp; of&nbsp; white&nbsp; blood&nbsp; cells,&nbsp; which&nbsp; may&nbsp; lead&nbsp; to&nbsp; more frequent infections; coexisting abnormal reduction in the number of red and white blood cells, as well as platelets.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p>Keep container in outer carton in order to protect it from light.</p><p>&nbsp;</p><p>Use the reconstituted solution within 12 hours.</p><p>Use the reconstituted and diluted solution within 12 hours.</p><p>&nbsp;</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally be not longer than 12 hours at not more than 25&deg;C.</p><p>&nbsp;</p><p>Do not use Pepsolan if you notice that the visual appearance has changed (e.g. if cloudiness or precipitation is observed).</p><p>&nbsp;</p><p>The content of the vial is meant for single use; any product that has remained in the vial has to be discarded.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Active substance: </strong>one vial Pepsolan &trade; 40 mg contains 45.11 mg pantoprazole sodium sesquihydrate, equivalent to 40 mg pantoprazole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other ingredients: </strong>the medicinal product contains no other ingredients than the active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pepsolan ™ 40 mg is a glass vial closed with a red rubber stopper and sealed by aluminium crimp with flip-off cap, containing a white to yellowish powder, i.e. the powder for solution for injection.

The vials are packed in carton boxes. Each box contains 1, 5, 10 or 20 glass vials. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>Marketing Authorisation Holder</strong></p><p>Sandoz GmbH, 6250 Kundl, Austria</p><p><strong>Manufacturer</strong></p><p>Lek Pharmaceuticals d.d., 1526 Ljubljana, Slovenia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                {10/2019}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار بيبسولان على المادة الفعّالة بانتوبرازول. يُعد عقار بيبسولان أحد &quot;مثبطات مضخات البروتون&quot; الانتقائية، وهو يقلل من كمية الحمض الذي يتم إفرازه لديك في المعدة. فهو يُستخدم لعلاج أمراض المعدة والأمعاء المتعلقة بالحمض.</p><p dir="RTL">يُحقن هذا المستحضر في الوريد ولن يتم إعطاؤه لك إلا إذا رأى طبيبك أنَّ تَلَقِّي عمليات الحقن الخاصة ببانتوبرازول أكثر ملاءمة لك في الوقت الحالي من أقراص بانتوبرازول. ستحل الأقراص محل عمليات الحقن الخاصة بك بمجرد أن يرى طبيبك أن ذلك مناسبًا.</p><p dir="RTL">&nbsp;</p><p>يُستخدم عقار بيبسولان لعلاج الآتي:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الْتِهاب المَريءِ الجَزْرِيّ. التهاب المريء لديك (الأنبوب الذي يربط الحلق بالمعدة لديك) المصحوب بارتجاع حمض المعدة.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح المعدة والإثنا عشر.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة زولينجر إليسون وغيرها من الحالات التي يتم فيها إفراز الكثير من الحمض في المعدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم عقار بيبسولان في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من حساسية تجاه بانتوبرازول أو أيٍّ من المكونات الأخرى الموجودة بهذا الدَّواء (المُدرجة في قسم: 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه الأدوية التي تحتوي على مثبطات مضخات البروتون الأخرى.</p><p dir="RTL">&nbsp;</p><p>تحذيرات واحتياطات</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك قبل استخدام عقار بيبسولان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل شديدة بالكبد. يُرجى إخبار طبيبك إذا كنت قد تعرضت من قبل لمشاكل في الكبد. سيقوم طبيبك بفحص إنزيمات الكبد لديك بشكل أكثر تكرارًا. في حالة ارتفاع إنزيمات الكبد، يجب إيقاف العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مثبطات البروتياز الخاص بفيروس نقص المناعة البشرية، مثل: أتازانافير (لعلاج عدوى فيروس نقص المناعة البشرية) في الوقت نفسه مع بانتوبرازول، فاسأل طبيبك للحصول على مشورة تتعلق بهذا الأمر تحديدًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُؤدي استخدام مثبط مضخات البروتون مثل: بانتوبرازول، خاصةً على مدار فترة أكثر من عام واحد، إلى حدوث زيادة طفيفة في خطر إصابتك بكسر في الحوض أو المعصم أو العمود الفقري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت مصابًا بهشاشة العظام، أو إذا كنت تتناول الكورتيكوستيرويدات (التي قد تزيد من خطر الإصابة بهشاشة العظام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج بعقار بيبسولان لمدة أكثر من ثلاثة أشهر، فمن المحتمل أن تنخفض مستويات الماغنسيوم لديك في الدم. يمكن ملاحظة انخفاض مستويات الماغنسيوم في هيئة حدوث إرهاق وانقباضات عضلية لا إرادية وتَوَهان وتشنجات ودوخة وزيادة في معدل ضربات القلب. إذا أصبت بأيٍّ من هذه الأعراض، فيُرجى إخبار طبيبك فورًا. من الممكن أيضًا أن يؤدي انخفاض مستويات الماغنسيوم إلى حدوث انخفاض في مستويات البوتاسيوم أو الكالسيوم في الدَّم. قد يقرر طبيبك إجراء اختبارات منتظمة بالدم؛ لمراقبة مستويات الماغنسيوم لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بصدد الخضوع لاختبار محدد بالدم (كروموجرانين &quot;أ&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بإحدى التفاعلات الجلدية بعد العلاج بدواء مماثل لعقار بيبسولان الذي يقلل من حمض المعدة.</p><p dir="RTL">إذا تعرضت للإصابة بطفح جلدي، خاصةً في المناطق المعرضة للشمس، فأخبر طبيبك بأسرع ما يمكن، حيث إنك قد تكون بحاجة إلى إيقاف علاجك بعقار بيبسولان. تذكر أيضًا ذكر أيِّ تأثيرات مرضية أخرى مثل الإصابة بألم في المفاصل لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور</strong>، قبل استخدام هذا الدَّواء أو بعد استخدامه، إذا لاحظت أيًّا من الأعراض التَّالية، والتي قد تكون علامة على حدوث مرض آخر أكثر خطورة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان غير مقصود بالوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء، وخاصة عند التكرار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء المصحوب بدم، قد يبدو ذلك مثل حبوب القهوة الداكنة في القيء لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت وجود دم في البراز لديك، والذي قد يبدو بمظهر أسود أو قطراني اللون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع أو ألم عند البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بدوت شاحبًا وتشعر بالضعف (فقر الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإِسْهال الشديد و/ أو المستمر، لأنَّ هذا الدواء يكون مرتبطًا بحدوث زيادة طفيفة في الإصابة بالإسهال المُعدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقرر طبيبك أنك بحاجة إلى الخضوع لبعض الاختبارات؛ لاستبعاد الإصابة بالمرض الخبيث لأنَّ بانتوبرازول يخفف أيضًا من أعراض السرطان وقد يُسبب تأخير تشخيصه. إذا استمرت الأعراض على الرَّغم من علاجك، سيتم النَّظر في إجراء المزيد من الفحوصات.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL">لا يوصى باستخدام عقار بيبسولان في الأطفال حيث أنه لم يتم إثبات فعاليته في الأطفال ممن تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p>استخدام عقار بيبسولان مع الأدوية الأخرى</p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجع ذلك إلى أن عقار بيبسولان قد يُؤثر على فعالية الأدوية الأخرى، لذلك أخبر طبيبك إذا كنت تتناول الآتي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل: كيتوكونازول، اتراكونازول وپوساکونازول (تُستخدم لعلاج العدوى الفطرية) أو إرلوتينيب (يُستخدم لعلاج بعض أنواع السرطان) لأنَّ عقار بيبسولان قد يوقف هذه الأدوية وغيرها من الأدوية عن العمل بشكل صحيح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين وفينوبروكومون، واللذان يؤثران على لزوجة الدم أو تسييله. قد تكون بحاجة إلى الخضوع لفحوصات إضافية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية، مثل: أتازانافير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات (يُستخدم لعلاج التهاب المفاصل الروماتويدي والصدفية والسرطان) - إذا كنت تتناول ميثوتريكسات فقد يوقف طبيبك علاجك مؤقتًا بعقار بيبسولان لأن بانتوبرازول بإمكانه زيادة مستويات ميثوتريكسات في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوفوكسامين (يُستخدم لعلاج الاكتئاب وغيره من الأمراض النفسية) - إذا كنت تتناول فلوفوكسامين، فقد يخفض طبيبك الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يُستَخدَم لعلاج العدوى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (هايبريكوم برفوراتام) (تُستخدم لعلاج الاكتئاب البسيط).</p><p dir="RTL">&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">لا توجد أية بيانات كافية عن استخدام بانتوبرازول في السيدات الحوامل. تم الإبلاغ عن إفراز العقار في لبن الأم من البشر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين طبيعيًّا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ عدم استخدام هذا الدواء، إلا إذا اعتبر طبيبك أن الفائدة بالنسبة لكِ تفوق الخطر المحتمل على جنينكِ أو طفلكِ.</p><p dir="RTL">&nbsp;</p><p>القيادة واستخدام الآلات</p><p dir="RTL">ليس لعقار بيبسولان أيُّ تأثير أو هناك تأثير لا يكاد يذكر في القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت للإصابة بآثار جانبية مثل الدوخة أو اضطراب الرؤية، فيجب عليك عدم ممارسة القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p>يحتوي عقار بيبسولان على الصوديوم</p><p>يحتوي هذا الدَّواء على أقل من 1 مللي مول (23 مجم) من الصوديوم بكل زجاجة، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعطيك/ ستعطيك الممرض(ة) أو الطبيب الخاص بك الجرعة اليومية في هيئة حقن في الوريد على مدار فترة تبلغ دقيقتين إلى 15 دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي:</p><p>بالنسبة للبالغين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>لعلاج قرح المعدة وقرح الإثنا عشر والْتِهاب المَريءِ الجَزْرِيّ</em><em>.</em></p><p dir="RTL">زجاجة واحدة (40 مجم بانتوبرازول) في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>بالنسبة للعلاج طويل الأمد لمتلازمة زولينجر إليسون وغيرها من الحالات التي يتم فيها إفراز حمض المعدة بكمية كبيرة</em></strong><strong><em>.</em></strong></p><p dir="RTL">زجاجتان (80 مجم بانتوبرازول) في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقوم طبيبك بتعديل الجرعة لاحقًا، اعتمادًا على الكمية التي تفرزها من حمض المعدة. إذا وصف لك استخدام أكثر من زجاجتين (80 مجم) في اليوم، فسيتم إعطاء الحقن بجرعتين متساويتين.</p><p dir="RTL">قد يصف طبيبك جرعة مؤقتة تبلغ أكثر من أربع زجاجات (160 مجم) في اليوم. إذا كان مستوى حمض المعدة لديك بحاجة إلى التَّحكم به بسرعة، فيجب أن تكون جرعة البدء البالغة 160 مجم (أربع زجاجات) كافية لخفض كمية حمض المعدة بشكل كافٍ.</p><p dir="RTL">&nbsp;</p><p>القصور الكبدي</p><p dir="RTL">إذا كنت تعاني من مشاكل شديدة بالكبد، فيجب أن تكون جرعة الحقن اليومية 20 مجم (نصف زجاجة) فقط.</p><p dir="RTL">&nbsp;</p><p>الاستخدام في الأطفال والمراهقين</p><p dir="RTL">لا يُوصى باستخدام هذه الحقن في الأطفال والمراهقين الأقل من 18 عامًا.</p><p dir="RTL">&nbsp;</p><p>إذا استخدمت كمية أكثر مما يجب من عقار بيبسولان</p><p dir="RTL">يتم التَّحقق من هذه الجرعات بعناية من قبل الممرض(ة) أو الطبيب الخاص بك؛ لذا فإنَّ تلقي جرعة زائدة أمرًا غير مرجح للغاية. لا توجد أية أعراض معروفة للجرعة الزائدة.</p><p dir="RTL">&nbsp;</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p>إذا تعرضت لأيٍّ من الآثار الجانبية التَّالية، فأخبر طبيبك فورًا، أو اتصل بقسم الطوارئ بأقرب مستشفى لك:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعلات حساسية خطيرة </strong><strong>(</strong><strong>معدّل التكرار نادر</strong><strong>: </strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>1000&nbsp;</strong><strong>شخص</strong><strong>):</strong> تورم اللسان و/ أو الحلق، صعوبة في البلع، شرى (طفح القراص)، صعوبات في التنفس، تورم تحسسي بالوجه (وذمة كوينكه/ وذمة وعائية)، دوخة شديدة مع ضربات قلب سريعة جدًّا وتعرق شديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات خطيرة بالجلد </strong><strong>(</strong><strong>معدل التكرار غير معروف</strong><strong>: </strong><strong>لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</strong><strong>): </strong>بثور بالجلد وتدهور سريع بحالتك العامة، تآكل (بما في ذلك نزيف طفيف) بالعينين أو الأنف أو الفم/ الشفتين أو الأعضاء التناسلية (متلازمة ستيفنز جونسون، متلازمة ليل، الاحمرار متعدد الأشكال) وحساسية تجاه الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات خطيرة أخرى </strong><strong>(</strong><strong>معدل التكرار غير معروف</strong><strong>: </strong><strong>لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</strong><strong>):</strong> اصفرار الجلد أو بياض العينين (تلف شديد بخلايا الكبد، يرقان) أو حُمى، طفح جلدي وتضخُّم الكلى أحيانًا مع تبول مؤلم وآلام أسفل الظهر (التهاب شديد بالكُلى)، ربما يؤدي إلى الفشل الكلوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">التهاب جدار الوريد وتجلط الدَّم (التهاب الوريد الخُثاري) بموضع حقن الدَّواء، سَلَائِل حميدة في المعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">صداع، دوخة، إِسْهال، الشعور بالإعياء، قيء، انتفاخ وغازات بالبطن (ريح)، إمساك، جفاف الفم، ألم بالبطن وشعور بعدم ارتياح، طفح جلدي، طفح ظاهر، طفح، حكة، الشعور بالضعف، الشعور بالإنهاك أو شعور عام بأنك لست على ما يرام، اضطرابات بالنوم، كسور في الحوض أو المعصم أو العمود الفقري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نادرة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">اضطراب بحاسة التَّذوق أو فقدها تمامًا، اضطرابات في الرؤية مثل عدم وضوح الرؤية، شرى (أرتكاريا)، ألم بالمفاصل، ألم بالعضلات، تغيرات بالوزن، ارتفاع درجة حرارة الجسم، حمى مرتفعة، تورم بالأطراف (وذمة طرفية)، تفاعلات حساسية، اكتئاب، تضخم الثدي لدى الذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نادرة جدًّا </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص)</p><p dir="RTL">&nbsp;تَوَهان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير معروفة </strong>(لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">هلوسة، ارتباك/ التباس (خاصة في المرضى الذين لديهم تاريخ من الإصابة بهذه الأعراض)، انخفاض مستوى الصوديوم بالدم، انخفاض مستوى الماغنسيوم بالدم (انظر القسم: 2)، الشعور بخدر، وخز، نخز &quot;الإبر أو المسامير&quot;، إحساس بالحرقة أو التنميل، طفح جلدي، ربما مع ألم بالمفاصل، التهاب بالأمعاء الغليظة مما يسبب الإصابة بالإِسْهال المائي المستمر.</p><p dir="RTL">&nbsp;</p><p>الآثار الجانبية التي تم التعرف عليها من خلال اختبارات الدَّم:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</p><p dir="RTL">ارتفاع بإنزيمات الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نادرة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">زيادة في البيليروبين، ارتفاع مستويات الدهون بالدَّم، هبوط حاد في تعداد خلايا الدَّم البيضاء المحببة في الدورة الدَّموية، مصحوب بحمى مرتفعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نادرة جدًّا </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص)</p><p dir="RTL">انخفاض في تعداد الصفائح الدموية مما قد يسبب تعرضك للنزيف أو الكدمات بشكل أكثر من المعتاد، انخفاض في تعداد خلايا الدَّم البيضاء مما قد يؤدي إلى الإصابة بالعدوى بشكل أكثر تكرارًا، انخفاض قائم غير طبيعي في تعداد خلايا الدم الحمراء والبيضاء، وكذلك الصفائح الدموية.</p><p dir="RTL">&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا أُصبت بأية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك. يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصَّلاحية المدون على الملصق والعبوة الكرتونية بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفَظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">احتفظ بالعبوة داخل العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصى باستخدام المحلول المُعَد في غضون 12 ساعة.</p><p dir="RTL">يُوصى باستخدام المحلول المُعَد والمُخَفف في غضون 12 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">من وجهة النَّظر الميكروبيولوجية، يجب استخدام المنتج فورًا. إذا لم يُستخدم على الفور، تكون مدة التَّخزين أثناء الاستخدام وظروف التَّخزين قبل الاستخدام مسؤولية المستخدم وعادة لن تكون أطول من 12 ساعة وفي درجة حرارة لن تزيد عن 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم عقار بيبسولان إذا لاحظت تغيرًا بالمظهر المرئي (على سبيل المثال: إذا لوحظ أن العقار غائمًا أو به&nbsp; ترسُّب).</p><p dir="RTL">&nbsp;</p><p dir="RTL">محتوى الزجاجة يكون مُعدًّا للاستخدام مرة واحدة. يجب التَّخلص من أيِّ منتج متبقٍّ في الزجاجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. ستُساعد هذه التَّدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعَّالة</strong><strong>: </strong>تحتوي زجاجة واحدة من عقار بيبسولان 40 مجم على 45.11 مجم من بانتوبرازول سيسكي هيدرات الصوديوم، ما يعادل 40 مجم بانتوبرازول.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong><strong>:</strong> لا يحتوي المنتج الدَّوائي على أية مكونات أخرى بخلاف المادة الفعَّالة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار بيبسولان 40 مجم عبارة عن زجاجة زجاجية مغلقة بسدادة مطاطية حمراء ومحكمة الإغلاق برقاقة من الألومنيوم مع غطاء قابل للنزع، تحتوي على مسحوق أبيض يميل إلى الأصفر، أي، المسحوق الخاص بإعداد محلول للحَقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه الزجاجات معبأة في عبوات كرتونية. تحتوي كل عبوة على 1، 5، 10 أو 20 زجاجة زجاجية.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التَّسويق</strong></p><p dir="RTL">شركة ساندوز المحدودة، 6250 كوندل، النمسا</p><p>&nbsp;</p><p><strong>جهة التَّصنيع</strong></p><p dir="RTL">شركة ليك للصناعات الدَّوائية، شركة مساهمة، 1526 ليوبليانا، سلوفينيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            {10/2019}.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pepsolan 40 mg powder for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 40 mg pantoprazole (as pantoprazole sodium sesquihydrate).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection. A white to yellowish powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reflux oesophagitis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastric and duodenal ulcer.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>This medicine should be administered by a healthcare professional and under appropriate medical supervision.</p><p>&nbsp;</p><p>Intravenous administration of Pepsolan is recommended only if oral administration is not appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral therapy is possible, treatment with Pepsolan IV should be discontinued and 40 mg pantoprazole p.o. should be administered instead.</p><p>&nbsp;</p><p><em><u>Posology</u></em></p><p><em>&nbsp;</em></p><p><u>Gastric and duodenal ulcer, reflux oesophagitis</u></p><p>The recommended intravenous dose is one vial of Pepsolan (40 mg pantoprazole) per day.</p><p>&nbsp;</p><p><u>Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions</u></p><p>For the long-term management of Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions patients should start their treatment with a daily dose of 80 mg Pepsolan .</p><p>&nbsp;</p><p>&nbsp;Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible&nbsp; but&nbsp; should not be applied longer than required for adequate acid control.</p><p>In case a rapid acid control is required, a starting dose of 2 x 80 mg Pepsolan is sufficient to manage a decrease of acid output into the target range (&lt; 10 mEq/h) within one hour in the majority of patients.</p><p>&nbsp;</p><p><em>Hepatic Impairment</em></p><p>A daily dose of 20 mg pantoprazole (half a vial of 40 mg pantoprazole) should not be exceeded in patients with severe liver impairment (see section 4.4).</p><p>&nbsp;</p><p><em>Renal Impairment</em></p><p>No dose adjustment is necessary in patients with impaired renal function (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is necessary in elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Pepsolan 40 mg powder for solution for injection in children aged under 18 years have not been established. Therefore, Pepsolan 40 mg powder for solution for injection is not recommended for use in patients below 18 years of age.</p><p>&nbsp;</p><p>Currently available data are described in section 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><em><u>Method of administration</u></em></p><p>A ready-to-use solution is prepared in 10 ml of sodium chloride 9 mg/ml (0.9 %) solution&nbsp; for injection.</p><p>For instructions for preparation see section 6.6. The prepared solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9 %) solution for injection or glucose monohydrate 55 mg/ml (5 %) solution for injection.</p><p>&nbsp;</p><p>After preparation the solution must be used within 12 hours.</p><p>&nbsp;</p><p>The medicinal product should be administered intravenously over 2 - 15 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles, or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gastric malignancy</u></p><p>Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may delay diagnosis. In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded.</p><p>Further investigation is to be considered if symptoms persist despite adequate treatment. <u>Hepatic impairment</u></p><p>In patients with severe liver impairment, the liver enzymes should be monitored during therapy. In the</p><p>case of a rise of the liver enzymes, the treatment should be discontinued (see section 4.2).</p><p>&nbsp;</p><p><u>Co-administration with HIV protease inhibitors</u></p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, due to significant reduction in their bioavailability (see section 4.5).</p><p>&nbsp;</p><p><u>Gastrointestinal infections caused by bacteria</u></p><p>Treatment with Pepsolan may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as Salmonella and Campylobacter or C. difficile.</p><p>Pantoprazole, like all proton pump inhibitors (PPIs), might be expected to increase the counts of bacteria normally present in the upper gastrointestinal tract. Treatment with Pepsolan may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as <em>Salmonella </em>and <em>Campylobacter.</em></p><p><em>&nbsp;</em></p><p><u>Hypomagnesaemia</u></p><p>Severe hypomagnesaemia has been reported in patients treated with PPIs like pantoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>&nbsp;</p><p><u>Bone fractures</u></p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p>&nbsp;</p><p><u>Subacute cutaneous lupus erythematosus (SCLE)</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical</p><p>&nbsp;</p><p>help promptly and the health care professional should consider stopping Pepsolan . SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p><u>Interference with laboratory tests</u></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Pepsolan treatment should be stopped for at least 5&nbsp; days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p>&nbsp;</p><p>Pepsolan contains sodium</p><p>This medicinal product contains less than 1 mmol (23 mg) sodium per vial, that is to say essentially sodium free.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Medicinal products with pH dependent absorption pharmacokinetics</u></p><p>Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with the absorption of other medicinal products where gastric pH is an important determinant of oral bioavailability, e.g. some&nbsp; azole antifungals such as ketoconazole, itraconazole, posaconazole and&nbsp; other medicine such as erlotinib.</p><p>&nbsp;</p><p><u>HIV protease inhibitors</u></p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir due to significant reduction in their bioavailability (see section 4.4).</p><p>If the combination of HIV protease inhibtiors with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g. virus load) is recommended. A pantoprazole dose of 20 mg per day should not be exceeded. Dosage of the HIV protease inhibitor may need to be adjusted.</p><p>&nbsp;</p><p><u>Coumarin anticoagulants (phenprocoumon or warfarin)</u></p><p>Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of warfarin, phenoprocoumon or INR. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin or phenoprocoumon concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding, and even&nbsp; death. Patients treated with pantoprazole and warfarin or phenprocoumon may need to be monitored for increase in INR and prothrombin time.</p><p>&nbsp;</p><p><u>Methotrexate</u></p><p>Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.</p><p>&nbsp;</p><p><u>Other interactions studies</u></p><p>&nbsp;</p><p>Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include oxidation by CYP3A4.</p><p>Interaction studies with medicinal products also metabolized with these pathways, like&nbsp; carbamazepine, diazepam, glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions.</p><p>&nbsp;</p><p>An interaction of pantoprazole with other medicinal products or compounds, which are metabolized using the same enzyme system, cannot be excluded.</p><p>&nbsp;</p><p>Results from a range of interaction studies demonstrate that pantoprazole does not affect the metabolism of active substances metabolised by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as ethanol) or does not interfere with p-glycoprotein related absorption of digoxin.</p><p>&nbsp;</p><p>There were no interactions with concomitantly administered antacids.</p><p>&nbsp;</p><p>Interaction studies have also been performed by concomitantly administering pantoprazole with the respective antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically relevant interactions were found.</p><p>&nbsp;</p><p><em>Medicinal products that inhibit or induce CYP2C19</em></p><p>Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole. A dose reduction may be considered for patients treated long-term with high doses of pantoprazole, or those with hepatic impairment.</p><p>Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s&nbsp; wort&nbsp; (Hypericum perforatum) may reduce the plasma concentrations of PPIs that are metabolized through these enzyme systems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/ neonatal toxicity of Pepsolan .</p><p>&nbsp;</p><p>Animal studies have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of Pepsolan during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient information on the excretion of pantoprazole in human milk but excretion into human milk has been reported. A risk to the newborns/infants cannot be excluded. Therefore, a decision on whether to discontinue breast-feeding or to discontinue/abstain from Pepsolan therapy should take into</p><p>&nbsp;</p><p>account the benefit of breast-feeding for the child, and the benefit of Pepsolan therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Approximately 5% of patients can be expected&nbsp; to experience adverse drug reactions (ADRs). The most commonly reported ADR is injection site thrombophlebitis. Diarrhoea and headache, occurred&nbsp;&nbsp; in approximately 1% of patients.</p><p>&nbsp;</p><p>The table below lists adverse reactions reported with pantoprazole, ranked under the following frequency classification:</p><p>&nbsp;</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>For all adverse reactions reported from post-marketing experience, it is not possible to apply any Adverse Reaction frequency and therefore they are mentioned with a &ldquo;not known&rdquo; frequency.</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Table 1: Adverse reactions with pantoprazole in clinical trials and post-marketing experience</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency System</strong></p><p><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis</p></td><td style="vertical-align:top"><p>Thrombo-</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>lymphatic system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cytopenia;</p></td></tr><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>(including</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>reactions and</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency System</strong></p><p><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactic shock)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidaemi as and lipid increases (triglycerides, cholesterol); Weight changes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyponatraemi a, Hypomagnesa emia (see section 4.4) Hypocalcaemi a in association with hypomagnese mia; Hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sleep disorders</p></td><td style="vertical-align:top"><p>Depression (and all aggravations)</p></td><td style="vertical-align:top"><p>Disorientatio n (and all aggravations)</p></td><td style="vertical-align:top"><p>Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these sym- ptoms in case of pre- existence)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache; Dizziness</p></td><td style="vertical-align:top"><p>Taste disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Disturbances in vision / blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Fundic gland polyps (benign)</p></td><td style="vertical-align:top"><p>Diarrhoea; Nausea / vomiting; Abdominal distension and bloating; Constipation; Dry mouth; Abdominal pain and discomfort</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Microscopic colitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver</p></td><td style="vertical-align:top"><p>Bilirubin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatocellular</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency System</strong></p><p><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>enzymes increased (transaminas- es, &gamma;-GT)</p></td><td style="vertical-align:top"><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>injury; Jaundice; Hepatocellular failure</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash / exanthema / eruption; Pruritus</p></td><td style="vertical-align:top"><p>Urticaria; Angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens- Johnson syndrome; Lyell syn- drome; Ery- thema multi- forme; Photo- sensitivity; Subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td><td style="vertical-align:top"><p>Arthralgia; Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasm as a consequence of electrolyte disturbances</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial nephritis (with possible progression to renal failure)</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site thrombo- phlebitis</p></td><td style="vertical-align:top"><p>Asthenia, fatigue and malaise</p></td><td style="vertical-align:top"><p>Body temperature increased; Oedema peripheral</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known symptoms of overdose in man.</p><p>Systemic exposure with up to 240 mg administered intravenously over 2 minutes were well tolerated. As pantoprazole is extensively protein bound, it is not readily dialysable.</p><p>In the case of an overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid related disorders, Proton pump inhibitors, ATC code: A02BC02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells.</p><p>&nbsp;</p><p>Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme, i.e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric&nbsp;&nbsp; acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin).&nbsp; The effect is the same whether the product is given orally or intravenously.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid hyperplasia). However, according to the studies&nbsp; conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.</p><p>&nbsp;</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>&nbsp;</p><p>&nbsp;</p><p>An influence of a long term treatment with pantoprazole exceeding one year cannot be completely ruled out on endocrine parameters of the thyroid according to results in animal studies.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetics</u></p><p>Pharmacokinetics do not vary after single or repeated administration. In the dose range of 10 to 80&nbsp; mg, the plasma kinetics of pantoprazole are linear after both oral and intravenous administration.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Pantoprazole&#39;s serum protein binding is about 98%. Volume of distribution is about 0.15 l/kg.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>The substance is almost exclusively metabolized in the liver. The main metabolic pathway is demethylation by CYP2C19 with subsequent sulphate conjugation, other metabolic pathways include oxidation by CYP3A4.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Terminal half-life is about 1 hour and clearance is&nbsp; about 0.1 l/h/kg. There were a few cases of&nbsp; subjects with delayed elimination. Because of the specific binding of pantoprazole to the proton&nbsp; pumps of the parietal cell the elimination half-life does not correlate with the much longer duration of action (inhibition of acid secretion).</p><p>Renal elimination represents the major route of excretion (about 80%) for the metabolites of pantoprazole, the rest is excreted with the faeces. The main metabolite in both the serum and urine is desmethylpantoprazole which is conjugated with sulphate. The half-life of the main metabolite&nbsp; (about</p><p>1.5 hours) is not much longer than that of pantoprazole.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Poor metabolisers</em></p><p>Approximately 3% of the European population lack a functional CYP2C19 enzyme and are called&nbsp; poor metabolisers. In these individuals the metabolism of pantoprazole is probably mainly catalysed by CYP3A4. After a single-dose administration of 40 mg pantoprazole, the mean area under the plasma concentration-time curve was approximately 6 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of pantoprazole.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose reduction is recommended when pantoprazole is administered to patients with impaired renal function (incl. dialysis patients). As with healthy subjects, pantoprazole&#39;s half-life is short. Only very small amounts of pantoprazole are dialyzed. Although the main metabolite has a moderately delayed half-life (2 - 3 h), excretion is still rapid and thus accumulation does not occur.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Although for patients with liver cirrhosis (classes A and B according to Child) the half-life values increased to between 7 and 9 h and the AUC values increased by a factor of 5 - 7, the maximum&nbsp; serum concentration only increased slightly by a factor of 1.5 compared with healthy subjects.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>A slight increase in AUC and Cmax in elderly volunteers compared with younger counterparts is also not clinically relevant.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Following administration of single intravenous doses of 0.8 or 1.6 mg/kg pantoprazole to children&nbsp; aged 2 - 16 years there was no significant association between pantoprazole clearance and age or weight. AUC and volume of distribution were in accordance with data from adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>&nbsp;</p><p>In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition, squamous cell papillomas were found in the forestomach of rats. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment. In the two-year rodent studies an increased number of liver tumours was observed in rats and in female mice and was interpreted as being due to pantoprazole&#39;s high metabolic rate in the liver.</p><p>&nbsp;</p><p>A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the pantoprazole- induced changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no harmful effects on the thyroid glands are expected.</p><p>&nbsp;</p><p>In animal reproduction studies, signs of slight foetotoxicity were observed at doses above 5 mg/kg. Investigations revealed no evidence of impaired fertility or teratogenic effects.</p><p>Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentration of pantoprazole in the foetus is increased shortly before birth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should not be prepared or mixed with solvents other than those stated in sections 4.2 and 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial: 24 months.

After reconstitution, or reconstitution and dilution, chemical and physical in use stability has been demonstrated for 12 hours at 25°C.
From a microbiological point of view, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Keep container in the outer carton, in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colourless type I glass vial, closed with a red rubber stopper and sealed by aluminium crimp with flip-off cap.</p><p>&nbsp;</p><p>Packs of 1, 5, 10 and 20 glass vials in carton box. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A ready-to-use solution is prepared by injecting 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection into the vial containing the powder. The appearance of the product after reconstitution is a colourless to faintly yellow solution. This solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or glucose monohydrate 55 mg/ml (5%) solution for injection. Glass or plastic containers should be used for dilution.</p><p>&nbsp;</p><p>After reconstitution, or reconstitution and dilution, chemical and physical in use stability has been demonstrated for 12 hours at 25&deg;C.</p><p>&nbsp;</p><p>From a microbiological point of view, the product should be used immediately.</p><p>&nbsp;</p><p>&nbsp;</p><p>Pepsolan should not be prepared or mixed with solvents other than those stated. The medicine should be administered intravenously over 2-15 minutes.</p><p>The contents of the vial are for single use only. Any product that has remained in the container or the visual appearance of which has changed (e.g. if cloudiness or precipitation is observed) should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH, 6250 Kundl, Austria 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                {10/2019}
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>